Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
On July 1, 2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 4 reporting that Chief Operating Officer Laura Lee Sandler received an employee stock option covering 25,000 shares of common stock at an exercise price of $11.80 per share. The option expires on June 30, 2035 and vests 25 % on July 1, 2026, with the remaining 75 % vesting in equal monthly installments thereafter (1⁄48 per month). After the grant, Sandler beneficially owns 25,000 derivative securities; no non-derivative share transactions were disclosed. The filing reflects an incentive-based award rather than an open-market purchase or sale, resulting in no immediate cash flow or share-count impact for investors.
On 07/01/2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 3 reporting the initial beneficial ownership of its newly appointed Chief Operating Officer, Laura Lee Sandler.
- Direct ownership: 213,084 shares of common stock.
- Derivative securities: • Warrant covering 99,996 shares at an exercise price of $7.80, expiring 07/14/2034. Vesting schedule: 25% on 04/03/2025, remaining shares vest monthly over the subsequent three years. • Employee stock option for 137,500 shares at $12.50, expiring 01/21/2035; vests 1/48 monthly beginning 01/01/2025.
- Potential total ownership: 450,580 shares if all derivatives vest and are exercised.
The disclosure signals meaningful insider alignment through equity ownership and a performance-linked vesting structure. No other transactions or financial metrics were included in this filing.